Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase 2 dose-ranging trial (NCT06164587) for its dual inflammasome inhibitor, K8, for geographic atrophy (GA). K8 is a member of a new class of inflammasome-inhibiting drugs called Kamuvudines. They…
FDA approves Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%. | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which is is the generic equivalent of RESTASIS 0.05%, a registered trademark of Allergan, an AbbVie company. Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator…
The Art and Science of Presbyopia Correction: Navigating the IOL Patient Journey | Ophthalmology Times
Presbyopia-correcting IOLs have undergone a dramatic transformation in recent years. The once-limited options for patients seeking reduced spectacle dependence after cataract surgery have evolved into a diverse and sophisticated array of IOL technologies, including trifocal, extended depth-of-focus (EDOF), small-aperture, light-adjustable,…
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada | Ophthalmology Times
(Image Credit: AdobeStock/platinumArt) Health Canada has approved Celltrion’s Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg), in both vial and pre-filled syringe format, for the treatment of all indications approved for Eylea, which in the US include neovascular (wet) age-related…
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ | Ophthalmology Times
(Image Credit: AdobeStock/Rawf8) LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZ for the treatment of presbyopia in adults…
Phase 1 trial confirms safety and tolerability of Huons’ dry eye therapy | Ophthalmology Times
(Image Credit: AdobeStock) Huons Co, a pharmaceutical subsidiary of Huons Group, received phase 1 Clinical Study Results (CSR) for HUC1-394, an eye drop for the treatment of dry eye disease (DED). HUC1-394 is a peptide-based eye drop for dry eyes,…
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/doucefleur) Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease type 1 (STGD1). According to the company, this marks the first successful pivotal trial in patients with the…
Kiora Pharmaceuticals receives patent for additional and novel formulations of KIO-100 compounds | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of the KIO-100 family of compounds from Kiora Pharmaceuticals. In July 2025, the company announced it had…